Home TMU Sitemap FAQ Links
正體中文
Home Ongoing Clinical Trials
Ongoing Clinical Trials

Institution
Principal Investigator
Protocol Title
Keyword
TMU-JIRB No. Protocol Title Institution / Principal Investigator Type of Study Phases of Clinical Trials for Drugs
N202404011 Global Study to Investigate Safety and Efficacy of Donanemab in Early Symptomatic Alzheimer’s Disease New Drug Phase Ⅲ
N202404021 A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1311 in Subjects with Advanced/Metastatic Solid Tumors New Drug Phase Ⅰ
N202404036 A short regimen for patients with rifampicin-resistant isoniazid-susceptible tuberculosis New Drug NA
N202404043 Metformin for the treatment of antipsychotic-induced hyperprolactinemia in patients with schizophrenia: a randomized, placebo-controlled, double-blind trial New Drug NA
N202404044 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults with Elevated Lipoprotein(a) who have Established Atherosclerotic Cardiovascular Disease or Are at Risk for a First Cardiovascular Event – ACCLAIM-Lp(a) New Drug Phase Ⅲ
N202404065 A PHASE III OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY OF ASTEGOLIMAB IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE New Drug Phase Ⅲ
N202405077 A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren’s Syndrome With Moderate-to-Severe Symptom State New Drug Phase Ⅲ
N202405080 A Phase 1/2 Study Evaluating the Safety and Efficacy of Amivantamab and Docetaxel Combination Therapy in Metastatic Non-small Cell Lung Cancer New Drug Phase Ⅰ
N202405096 A Phase 3, Open-label Extension Study to Evaluate the Safety and Efficacy of MK-0616 in Adults With Hypercholesterolemia New Drug Phase Ⅲ
N202405102 A Randomized, Open-label, Phase 3 Study of MK-2870 vs. Platinum Doublets in Participants With EGFR-mutated, Advanced Nonsquamous Nonsmall Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors New Drug Phase Ⅲ
1 2 16 17 18 19 20 21 22 51 52 / 52

TOP